November 23, 2018 / 6:18 AM / 19 days ago

BRIEF-European Commission Approves Spark Therapeutics' Luxturna

Nov 23 (Reuters) - Spark Therapeutics Inc:

* EUROPEAN COMMISSION APPROVES SPARK THERAPEUTICS’ LUXTURNA® (VORETIGENE NEPARVOVEC), A ONE-TIME GENE THERAPY FOR INHERITED RETINAL DISEASE CAUSED BY CONFIRMED BIALLELIC RPE65 MUTATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below